Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sanjay Popat

Showing results (111-120 of 272) with videos related to

Pageof 28
Sort By:
Future Oncology (London, England)|July 7, 2018
Patient selection for anti-PD-1/PD-L1 therapy in advanced non-small-cell lung cancer: implications for clinical practiceRaffaele Califano, Rohit Lal, Conrad Lewanski, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 14, 2020
Afatinib for the Treatment of NSCLC Harboring Uncommon EGFR Mutations: A Database of 693 CasesJames Chih-Hsin Yang, Martin Schuler, Sanjay Popat, et al.
European Journal of Cancer (Oxford, England : 1990)|November 1, 2011
Establishing an EGFR mutation screening service for non-small cell lung cancer - sample quality criteria and candidate histological predictorsAlexandra F Leary, David Gonzalez de Castro, Andrew G Nicholson, et al.
JCO Oncology Practice|September 11, 2020
Case of Fatal Immune-Related Skin Toxicity From Sequential Use of Osimertinib After Pembrolizumab: Lessons for Drug Sequencing in Never-Smoking Non-Small-Cell Lung CancerWanyuan Cui, Chantal Cotter, Katherina Bernadette Sreter, et al.
Expert Review of Anticancer Therapy|February 5, 2026
The role of zongertinib, a highly selective tyrosine kinase inhibitor, in targeting <i>HER2</i>-mutant NSCLC: a bench-to-bedside reviewJohn V Heymach, Sanjay Popat, Egbert F Smit, et al.
Lung Cancer (Amsterdam, Netherlands)|March 21, 2021
Health-related quality of life in the randomized phase III trial of brigatinib vs crizotinib in advanced ALK inhibitor-naive ALK + non-small cell lung cancer (ALTA-1L)Maria Rosario Garcia Campelo, Huamao M Lin, Yanyan Zhu, et al.
Lung Cancer (Amsterdam, Netherlands)|March 20, 2023
Anti-angiogenic agents for NSCLC following first-line immunotherapy: Rationale, recent updates, and future perspectivesMartin Reck, Sanjay Popat, Christian Grohé, et al.
Lung Cancer (Amsterdam, Netherlands)|October 8, 2015
Response evaluation in mesothelioma: Beyond RECISTLin Cheng, Nina Tunariu, David J Collins, et al.
Lung Cancer (Amsterdam, Netherlands)|May 9, 2021
Safety monitoring of two and four-weekly adjuvant durvalumab for patients with stage III NSCLC: implications for the COVID-19 pandemic and beyondKroopa Joshi, Abdul Muhith, Mariam Obeid, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 2, 2008
Good vibrations and the power of positron thinking: positron emission tomography and endoscopic ultrasound in staging of mesothelioma-two case reportsCraig P Carden, James S Myerson, Sanjay Popat, et al.
Pageof 28

Showing results (111-120 of 272) with videos related to

Sort By:
Pageof 28
Future Oncology (London, England)|July 7, 2018
Patient selection for anti-PD-1/PD-L1 therapy in advanced non-small-cell lung cancer: implications for clinical practiceRaffaele Califano, Rohit Lal, Conrad Lewanski, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 14, 2020
Afatinib for the Treatment of NSCLC Harboring Uncommon EGFR Mutations: A Database of 693 CasesJames Chih-Hsin Yang, Martin Schuler, Sanjay Popat, et al.
European Journal of Cancer (Oxford, England : 1990)|November 1, 2011
Establishing an EGFR mutation screening service for non-small cell lung cancer - sample quality criteria and candidate histological predictorsAlexandra F Leary, David Gonzalez de Castro, Andrew G Nicholson, et al.
JCO Oncology Practice|September 11, 2020
Case of Fatal Immune-Related Skin Toxicity From Sequential Use of Osimertinib After Pembrolizumab: Lessons for Drug Sequencing in Never-Smoking Non-Small-Cell Lung CancerWanyuan Cui, Chantal Cotter, Katherina Bernadette Sreter, et al.
Expert Review of Anticancer Therapy|February 5, 2026
The role of zongertinib, a highly selective tyrosine kinase inhibitor, in targeting <i>HER2</i>-mutant NSCLC: a bench-to-bedside reviewJohn V Heymach, Sanjay Popat, Egbert F Smit, et al.
Lung Cancer (Amsterdam, Netherlands)|March 21, 2021
Health-related quality of life in the randomized phase III trial of brigatinib vs crizotinib in advanced ALK inhibitor-naive ALK + non-small cell lung cancer (ALTA-1L)Maria Rosario Garcia Campelo, Huamao M Lin, Yanyan Zhu, et al.
Lung Cancer (Amsterdam, Netherlands)|March 20, 2023
Anti-angiogenic agents for NSCLC following first-line immunotherapy: Rationale, recent updates, and future perspectivesMartin Reck, Sanjay Popat, Christian Grohé, et al.
Lung Cancer (Amsterdam, Netherlands)|October 8, 2015
Response evaluation in mesothelioma: Beyond RECISTLin Cheng, Nina Tunariu, David J Collins, et al.
Lung Cancer (Amsterdam, Netherlands)|May 9, 2021
Safety monitoring of two and four-weekly adjuvant durvalumab for patients with stage III NSCLC: implications for the COVID-19 pandemic and beyondKroopa Joshi, Abdul Muhith, Mariam Obeid, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 2, 2008
Good vibrations and the power of positron thinking: positron emission tomography and endoscopic ultrasound in staging of mesothelioma-two case reportsCraig P Carden, James S Myerson, Sanjay Popat, et al.
Pageof 28